Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis.
Elisabetta CocconcelliNicol BernardinelloGioele CastelliSimone PetraruloSerena BellaniMarina SaettaPaolo SpagnoloElisabetta BalestroPublished in: International journal of molecular sciences (2023)
Sarcoidosis is a multisystemic disease of unknown etiology characterized by the formation of granulomas in various organs, especially lung and mediastinal hilar lymph nodes. The clinical course and manifestations are unpredictable: spontaneous remission can occur in approximately two thirds of patients; up to 20% of patients have chronic course of the lung disease (called advanced pulmonary sarcoidosis, APS) resulting in progressive loss of lung function, sometimes life-threatening that can lead to respiratory failure and death. The immunopathology mechanism leading from granuloma formation to the fibrosis in APS still remains elusive. Recent studies have provided new insights into the genetic factors and immune components involved in the clinical manifestation of the disease. In this review we aim to summarize the clinical-prognostic characteristics and molecular pathways which are believed to be associated with the development of APS.
Keyphrases
- end stage renal disease
- lymph node
- lung function
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- respiratory failure
- cystic fibrosis
- multiple sclerosis
- patient reported outcomes
- genome wide
- rheumatoid arthritis
- gene expression
- mechanical ventilation
- systemic lupus erythematosus
- early stage
- patient reported
- single molecule
- ulcerative colitis
- drug induced